Aβ1-40

By Targets:	Amyloid-β (13) Calcium Channel (1) Cholinesterase (ChE) (1) Endogenous Metabolite (1) Fluorescent Dye (1) Histamine Receptor (1) Liposome (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) γ-secretase (1)
By Research Areas:	Neurological Disease (15)
Oligonucleotides:	Liposomal Film-forming Agents (1) Emulsifiers (1)

Targets Recommended: WDR5

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153416

QR-0217	Amyloid-β	Neurological Disease
QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC₅₀ value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .

HY-N0249

Saikosaponin C	Amyloid-β	Neurological Disease
Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

HY-117957

BMS-932481	γ-secretase	Neurological Disease
BMS-932481 is an orally active modulator for γ-secretase, selectively reduce Aβ1-42 and Aβ1-40 production, with IC₅₀s of 6.6 and 25.3 nM, respectively .

HY-168031

AChE/BChE-IN-21	Histamine Receptor Calcium Channel Cholinesterase (ChE) Reactive Oxygen Species (ROS) Amyloid-β	Neurological Disease
AChE/BChE-IN-21 is a histamine H₃ receptor antagonist, calcium channel blocker, and acetylcholinesterase inhibitor. AChE/BChE-IN-21 exhibits neuroprotective activity against H₂O₂ and Aβ_1-40, and can restore cognitive function in AD mice .

HY-P10628

β Amyloid (1-14), human	Amyloid-β	Neurological Disease
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .

HY-P3860

Biotinyl-Amyloid β-Protein (1-42) (ammonium)	Amyloid-β	Neurological Disease
Biotinyl-Amyloid β-Protein (1-42) ammonium is a biotinylated Amyloid β-Protein (1-42) (HY-P1363). Biotinyl-Amyloid β-Protein (1-42) ammonium can be used for the research of Aβ1-42 converts to Aβ1-40 in brain .

HY-P991534

PF-04382923	Amyloid-β	Neurological Disease
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .

HY-N0249R

Saikosaponin C (Standard)	Reference Standards Amyloid-β	Neurological Disease
Saikosaponin C (Standard) is the analytical standard of Saikosaponin C. This product is intended for research and analytical applications. Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

HY-P990109

Aducanumab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC₅₀s of >1 μM and 0.2 nM for monomeric Aβ_1-40 and fibrillar Aβ_1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .

HY-P5906

*Citrullinated amyloid-β (1-40) peptide (human)* Citrullinated Aβ (1-40); Citrullinated Aβ40	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .

HY-N0322B

Cholesterol (Excipient, GMP Like)	Liposome Endogenous Metabolite	Others
Cholesterol (Excipient, GMP Like) is the GMP Like class Cholesterol (HY-N0322), and can be used as pharmaceutical excipients. Cholesterol is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity. In Vitro: Cholesterol (200 μg/mL; 40 h) increases the production of newly synthesized β-amyloid protein and enhances the secretion of Aβ_1-40 in HEK cells transfected with APP . In Vivo: Cholesterol (0.5% cholesterol in diet; oral; once daily; 7 days) increases plasma cholesterol in the hamster model, while the cholesterol absorption inhibitor SCH 48461 (10 mg/kg; oral gavage; once daily; 7 days) inhibits cholesterol absorption and reduces plasma cholesterol . Cholesterol (1% cholesterol + 0.5% bile acid in diet; oral; once daily; 7 days) increases plasma cholesterol levels in the male CD rat model, while SCH 48461 (2 mg/kg; oral; once daily; 7 days) reduces hepatic cholesterol ester accumulation . Cholesterol (0.25% cholesterol + 22% saturated fat diet; oral; once daily; 3 weeks) increases VLDL+LDL cholesterol levels in the rhesus monkey model, while SCH 48461 (0.2 mg/kg; oral; once daily; 3 weeks) maintains baseline levels and inhibits cholesterol absorption .

HY-P2549

Biotin-β-Amyloid (1-40)	Fluorescent Dye	Neurological Disease
Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-β-(1-40) peptide.

HY-111513

4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine	Amyloid-β	Neurological Disease
4-(6-Bromo-2-benzothiazolyl)-N-methylbenzenamine is a potent amyloid imaging agent which binds to *Amyloid-β* (1-40) with a K_D of 1.7 nM.

HY-134894A

Glycerophosphorylethanolamine sodium GroPEtn sodium	Amyloid-β	Neurological Disease
Glycerophosphorylethanolamine (GroPEtn) sodium is an active phosphodiester metabolite of Phosphatidylethanolamine (HY-W250118). Glycerophosphorylethanolamine sodium promotes the aggregation of amyloid β-protein (Aβ (1-40)) in vitro. Glycerophosphorylethanolamine sodium can be used in the field of neurodegenerative diseases, such as Alzheimer’s disease research .

HY-P2551

Biotin-β-Amyloid (17-40)	Amyloid-β	Neurological Disease
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .

HY-P5370

Scrambled β-amyloid (1-40)	Amyloid-β	Others
Scrambled β-amyloid (1-40) is a biological active peptide. (Aβ (1-40) together with Aβ (1-42) are two major C-terminal variants of the Aβ protein constituting the majority of Aβs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. This peptide is the scrambled sequence of Abeta 1-40 HY-P0265)

Cat. No.	Product Name	Target	Research Area

HY-P10628

β Amyloid (1-14), human	Amyloid-β	Neurological Disease
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .

HY-P3860

Biotinyl-Amyloid β-Protein (1-42) (ammonium)	Amyloid-β	Neurological Disease
Biotinyl-Amyloid β-Protein (1-42) ammonium is a biotinylated Amyloid β-Protein (1-42) (HY-P1363). Biotinyl-Amyloid β-Protein (1-42) ammonium can be used for the research of Aβ1-42 converts to Aβ1-40 in brain .

HY-P5906

*Citrullinated amyloid-β (1-40) peptide (human)* Citrullinated Aβ (1-40); Citrullinated Aβ40	Amyloid-β	Neurological Disease
Citrullinated amyloid-β (1-40) peptide (human) (Citrullinated Aβ (1-40)) is a modified form of β-Amyloid (1-40) (HY-P0265) with a citrullination at the Arg5 site. Citrullinated amyloid-β (1-40) peptide (human) exhibits increased transient formation of soluble oligomers and insoluble aggregates composed of distorted parallel β-sheets compared with unmodified β-Amyloid (1-40) .

HY-P2549

Biotin-β-Amyloid (1-40)	Fluorescent Dye	Neurological Disease
Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-β-(1-40) peptide.

HY-P2551

Biotin-β-Amyloid (17-40)	Amyloid-β	Neurological Disease
Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .

HY-P5967

Acetly-β Amyloid(15-20), Amide	Peptides	Neurological Disease
Acetly-β Amyloid (15-20), Amide is a peptides fragment. Acetly-β Amyloid (15-20), Amide inhibits the β-sheet formation and stabilizes structure of Aβ (1–40) peptide. Acetly-β Amyloid (15-20), Amide can be used in study Alzheimer’s disease .

HY-P5370

Scrambled β-amyloid (1-40)	Amyloid-β	Others
Scrambled β-amyloid (1-40) is a biological active peptide. (Aβ (1-40) together with Aβ (1-42) are two major C-terminal variants of the Aβ protein constituting the majority of Aβs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. This peptide is the scrambled sequence of Abeta 1-40 HY-P0265)

Cat. No.	Product Name	Target	Research Area

HY-P991534

PF-04382923	Amyloid-β	Neurological Disease
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the amyloid-β peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .

HY-P990109

Aducanumab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC₅₀s of >1 μM and 0.2 nM for monomeric Aβ_1-40 and fibrillar Aβ_1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0249

Saikosaponin C	Triterpenes Structural Classification Terpenoids Source classification Umbelliferae Plants Carphephorus corymbosus (Nutt.) Torr. & A.Gray	Amyloid-β
Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

HY-N0249R

Saikosaponin C (Standard)	Triterpenes Structural Classification Terpenoids Source classification Umbelliferae Plants Carphephorus corymbosus (Nutt.) Torr. & A.Gray	Reference Standards Amyloid-β
Saikosaponin C (Standard) is the analytical standard of Saikosaponin C. This product is intended for research and analytical applications. Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

Cat. No.	Product Name		Classification

HY-N0322B

Cholesterol (Excipient, GMP Like)		Emulsifiers Liposomal Film-forming Agents
Cholesterol (Excipient, GMP Like) is the GMP Like class Cholesterol (HY-N0322), and can be used as pharmaceutical excipients. Cholesterol is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity. In Vitro: Cholesterol (200 μg/mL; 40 h) increases the production of newly synthesized β-amyloid protein and enhances the secretion of Aβ_1-40 in HEK cells transfected with APP . In Vivo: Cholesterol (0.5% cholesterol in diet; oral; once daily; 7 days) increases plasma cholesterol in the hamster model, while the cholesterol absorption inhibitor SCH 48461 (10 mg/kg; oral gavage; once daily; 7 days) inhibits cholesterol absorption and reduces plasma cholesterol . Cholesterol (1% cholesterol + 0.5% bile acid in diet; oral; once daily; 7 days) increases plasma cholesterol levels in the male CD rat model, while SCH 48461 (2 mg/kg; oral; once daily; 7 days) reduces hepatic cholesterol ester accumulation . Cholesterol (0.25% cholesterol + 22% saturated fat diet; oral; once daily; 3 weeks) increases VLDL+LDL cholesterol levels in the rhesus monkey model, while SCH 48461 (0.2 mg/kg; oral; once daily; 3 weeks) maintains baseline levels and inhibits cholesterol absorption .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Name
Email *

	Sorry, but the email address you supplied was invalid.

Aβ1-40

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

Natural
Products